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The expansion of the white adipose tissue (WAT) in obesity goes along with increased
mechanical, metabolic and inflammatory stress. How adipocytes resist this stress is still
poorly understood. Both in human and mouse adipocytes, the transcriptional co-activators
YAP/TAZ and YAP/TAZ target genes become activated during obesity. When fed a high-fat
diet (HFD), mice lacking YAP/TAZ in white adipocytes develop severe lipodystrophy with
adipocyte cell death. The pro-apoptotic factor BIM, which is downregulated in adipocytes of
obese mice and humans, is strongly upregulated in YAP/TAZ-deficient adipocytes under
HFD, and suppression of BIM expression reduces adipocyte apoptosis. In differentiated
adipocytes, TNFα and IL-1β promote YAP/TAZ nuclear translocation via activation of RhoA-
mediated actomyosin contractility and increase YAP/TAZ-mediated transcriptional regula-
tion by activation of c-Jun N-terminal kinase (JNK) and AP-1. Our data indicate that the YAP/
TAZ signaling pathway may be a target to control adipocyte cell death and compensatory
adipogenesis during obesity.
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Obesity is a serious health problem as it is a strong riskfactor for the development of type-2 diabetes, cardio-vascular diseases, and cancer1–6. In obesity, the adipose
tissue undergoes dynamic remodeling including an increase in
size (hypertrophy) and number of adipocytes (hyperplasia), an
infiltration by immune cells, and the development of tissue
fibrosis7–12. In the obese adipose tissue, adipocytes are exposed to
different forms of stress. This includes hypoxia, oxidative stress,
metabolic stress, mechanical stress from hypertrophy, and
inflammatory stress due to infiltration of the adipose tissue by
immune cells and increased levels of cytokines13–19. Different
forms of cellular stress can activate extrinsic and intrinsic path-
ways of cell death resulting in adipocyte apoptosis20–23. There are
also anti-apoptotic, pro-survival pathways activated in adipocytes
of the obese adipose tissue, which protect adipocytes against cell
death. This is indicated by various mouse models with defects in
pro-survival pathways, which show strongly increased adipocyte
death during obesity24–26. However, the mechanisms protecting
adipocytes from uncontrolled cell death during obesity are still
poorly understood.
YAP and its paralog TAZ are transcriptional cofactors, which
regulate various cell functions including cell proliferation, dif-
ferentiation, and cell survival by integrating different cellular
signaling pathways27–30. Their nuclear translocation and activity
are controlled by several upstream signaling pathways. Activation
of the Hippo pathway results in phosphorylation of YAP/TAZ by
LATS kinase, leading to the cytoplasmic retention and degrada-
tion of YAP/TAZ30–32. In addition, G-protein-mediated signaling
pathways involving G12/G13 or Gq/G1133,34, as well as extra-
cellular matrix stiffness and cytoskeletal tension, can promote
nuclear translocation and activation of YAP/TAZ28,35–37. Nuclear
YAP/TAZ can co-activate or co-repress numerous genes involved
in cell proliferation, differentiation, and survival by interacting
with different transcription factors of which the TEAD (TEA
domain) family transcription factors are the best
characterized32,38–40. Given that YAP and TAZ play vital func-
tions in cell survival, we hypothesized that YAP and TAZ are
crucial for adipocyte homeostasis.
Here we show that adipocyte YAP and TAZ are activated
during obesity and induce upregulation of anti-apoptotic and
downregulation of pro-apoptotic factors such as BIM (Bcl-2
interacting mediator of cell death), and thereby promote adipo-
cyte survival in diet-induced obesity.
Results
Obesity promotes activation of YAP and TAZ in human and
mouse white adipocytes. To test whether YAP and TAZ activity
in white adipocytes is affected during obesity, we examined the
subcellular localization of YAP and TAZ, as well as YAP/TAZ
target gene expression in white adipocytes of humans and mice.
In human visceral adipocytes from lean subjects (body mass
index < 25), YAP and TAZ were localized equally in the cytosol
and nucleus, whereas YAP/TAZ were predominantly detected in
the nuclei of human visceral adipocytes from obese subjects (body
mass index > 30) (Fig. 1a, b). Quantitative reverse transcriptase
PCR (RT-PCR) showed that expression of YAP/TAZ target genes,
such as Cyr61, AmotL2, and Lats2, was upregulated in adipocytes
of obese subjects (Fig. 1c). Similarly, in adipose tissue from mice
fed a standard diet (SD), YAP and TAZ were localized both in the
cytosol and nucleus (Fig. 1d, e), whereas 4 weeks of high-fat diet
(HFD) feeding resulted in a strong increase in nuclear localization
of YAP/TAZ (Fig. 1d, e), both in the epididymal (visceral) and the
inguinal (subcutaneous) white adipose tissue (WAT). Quantita-
tive RT-PCR showed increased expression of YAP/TAZ target
genes in adipocytes from HFD-fed mice (Fig. 1f). These data
indicate that obesity in humans and mice goes along with
increased activation of YAP and TAZ in white adipocytes.
Adipocyte-specific YAP and TAZ deficiency leads to increased
adipocyte death during obesity. To examine the functions of
YAP and TAZ in white adipocytes, we generated inducible
adipocyte-specific YAP- and TAZ-deficient mice by crossing mice
carrying floxed alleles of Yap and Taz (Yapfl/fl;Tazfl/fl) with the
Adipoq-CreERT2 mouse line41. Adipocyte-specific, tamoxifen-
inducible Yap/Taz-deficient mice (Adipoq-CreERT2; Yapfl/fl;
Tazfl/fl, hereafter termed iAd-Yap/Taz-KO) showed strong
recombination of both floxed alleles in white adipocytes, resulting
in loss of YAP and TAZ proteins (Supplementary Fig. 1a). On SD,
iAd-Yap/Taz-KO mice showed no difference in total body weight,
glucose tolerance, or fat mass compared to wild-type littermates
(Supplementary Fig. 1b–d). To test whether activation of YAP
and TAZ during obesity affects adipocyte function, iAd-Yap/Taz-
KO mice were fed a HFD. After 12 weeks of HFD feeding, iAd-
Yap/Taz-KO mice gained significantly less weight compared to
wild-type littermates (Fig. 2a). Fasting blood glucose levels were
similar between both groups, but iAd-Yap/Taz-KO mice showed
an improved glucose tolerance compared to wild-type littermates
(Fig. 2b). The mass of the visceral WAT (vWAT) and sub-
cutaneous WAT (sWAT) of iAd-Yap/Taz-KO mice was markedly
reduced compared to wild-type littermates (Fig. 2c), whereas
body size and mass of other tissues including interscapular brown
adipose tissue (BAT) was unchanged (Supplementary Fig. 2a, b).
These changes were not observed in mice with induced
adipocyte-specific loss of YAP or TAZ alone (Fig. 2a, c and
Supplementary Fig. 2c), indicating that both transcriptional reg-
ulators have overlapping functions in adipocytes. Adipocyte
morphology and average cell size were not changed in iAd-Yap/
Taz-KO mice (Fig. 2d and Supplementary Fig. 2d, e), but the total
number of adipocytes was strongly reduced in the visceral and
sWAT (Fig. 2e). We also found an increased number of crown-
like structures and of macrophages as well as an increased
number of cells undergoing apoptosis as determined by TUNEL
(terminal deoxynucleotidyl transferase dUTP nick end labeling)
assay in the WAT of iAd-Yap/Taz-KO mice (Fig. 2d, f–h). These
data indicate that loss of YAP and TAZ results in increased
adipocyte death during obesity.
Despite very high recombination efficiency in adipocytes
resulting in loss of YAP and TAZ shortly after tamoxifen
treatment (Supplementary Fig. 1a), we noticed that, after 16 weeks
of HFD, Yap/Taz expression was similar to wild-type mice
(Supplementary Fig. 2f). To test whether the increased adipocyte
cell death due to loss of YAP and TAZ leads to increased
adipogenesis resulting in accumulation of newly formed wild-type
adipocyte in iAd-Yap/Taz-KO mice, we performed adipocyte
pulse-chase experiments42. We therefore crossed adipocyte-
specific, tamoxifen-inducible Cre transgenic mice (Adipoq-
CreERT2) with the mT/mG Cre reporter line, which switches
from membrane-targeted Tomato expression to membrane-
targeted enhanced green fluorescent protein (EGFP) expression
upon Cre-mediated recombination (Fig. 2i)43. One week after
tamoxifen injection, nearly all adipocytes showed green fluores-
cence (Supplementary Fig. 2g), and 8 weeks after induction of Cre
activity and feeding with SD, 4–5% of the adipocytes in the
vWAT of both wild-type and iAd-Yap/Taz-KO mice were
Tomato-positive (Supplementary Fig. 2h). However, whereas in
wild-type mice fed an HFD for 8 and 16 weeks, 13% and 25% of
adipocytes were Tomato-positive (Fig. 2j, k), 26% and 74% of
adipocytes showed red fluorescence in adipocyte-specific Yap/Taz
knockouts (Fig. 2j, k). This indicates that they had formed from
Tomato-positive adipocyte precursor cells after induction with
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19229-3
2 NATURE COMMUNICATIONS |         (2020) 11:5455 | https://doi.org/10.1038/s41467-020-19229-3 | www.nature.com/naturecommunications
tamoxifen and HFD feeding. Thus, loss of adipocyte YAP/TAZ in
obese iAd-Yap/Taz-KO mice leads to increased adipocyte death
and increased adipogenesis resulting in the replacement of the
majority of YAP/TAZ-deficient adipocytes by wild-type adipo-
cytes after a few months.
Constitutive loss of adipocyte YAP and TAZ leads to adipocyte
death and lipodystrophy under HFD. To avoid replacement of
Yap/Taz-deficient adipocytes by wild-type adipocytes in iAd-Yap/
Taz-KO mice, we generated constitutive adipocyte-specific Yap/
Taz-deficient mice by crossing Yapfl/fl;Tazfl/fl mice with Adipoq-Cre
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Fig. 1 Obesity promotes YAP/TAZ activation in white adipocytes. a, d vWAT from lean (body mass index < 25) and obese subjects (body mass index >
30) (a) or from mice fed HFD for 4 weeks and mice fed standard diet (SD) (d) was stained with anti-YAP/TAZ antibody, DAPI, CellMask to visualize
adipocyte plasma membranes and LipidTOX (lipid). Scale bars: 10 µm. b, e Quantification of YAP/TAZ localization to the nucleus (N) or cytosol (C) in
visceral white adipocyte of human lean (n= 5), and obese subjects (n= 5) (b) or in the visceral (vWAT) and subcutaneous white adipose tissue (sWAT)
from standard diet (SD)-fed (n= 3) and HFD-fed mice (n= 3) (e). c, f Expression of YAP/TAZ target genes, and of Yap and Taz in white adipocyte
isolated from human visceral adipocytes of lean (n= 8) and obese subjects (n= 10) (c) or from the vWAT of mice fed HFD (n= 6) or standard diet (SD)
(n= 6) for 4 weeks (f). Data are presented as the mean ± SEM; *p≤ 0.05 and **p≤ 0.01 (compared to lean humans or standard diet (SD)-fed mice in b, e)
(unpaired Student’s t-test). Source data are provided as a Source Data file.
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mice44 (Adipoq-Cre;Yapfl/fl;Tazfl/fl, henceforth termed Ad-Yap/
Taz-KO), which were born at the expected Mendelian ratio
without any apparent abnormality. On SD, Ad-Yap/Taz-KO mice
showed normal total body weight and glucose tolerance (Sup-
plementary Fig. 3a, b). There was also no difference in fat tissue
mass between Ad-Yap/Taz-KO mice and wild-type animals, but
Ad-Yap/Taz-KO mice showed a slight increase in crown-like
structures in their adipose tissue (Supplementary Fig. 3c, d).
However, after 10 weeks of HFD feeding, the total body weight of
Ad-Yap/Taz-KO mice started to be significantly lower than that
of wild-type littermates (Fig. 3a). This was accompanied by an
increased glucose tolerance and a massive reduction in the mass
of both vWAT and sWAT in Ad-Yap/Taz-KO mice (Fig. 3b, c).
Histological analysis of adipose tissue from HFD-fed Ad-Yap/
Taz-KO mice showed increased numbers of TUNEL-positive
adipocytes undergoing apoptosis as well as increased numbers of
crown-like structures already after 4 weeks of HFD feeding
(Fig. 3d, e). After 14 weeks of HFD feeding, Ad-Yap/Taz-KO
mice showed a strongly reduced expression of the adipocyte-
specific lipid droplet protein perilipin-1, accumulation of mac-
rophages, and increased expression of M2 macrophage marker
genes including Arg1, Mrc1, and IL-10, whereas expression of M1
marker genes such as iNOS was rather decreased (Fig. 3f–h).
Furthermore, expression of several adipocyte marker genes, such
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as adiponectin (Adipoq), Leptin, Resistin, Glut4, Pparγ, and
Fabp4, were strongly reduced in the WAT of Ad-Yap/Taz-KO
mice (Fig. 3i). Collectively, these data confirm that YAP and TAZ
are essential for adipocyte survival during obesity, and that loss of
YAP and TAZ leads to adipocyte apoptosis and lipodystrophy.
YAP and TAZ regulate expression of genes encoding pro- and
anti-apoptotic factors in adipocytes. The massive increase in
apoptotic adipocyte death in obese mice after loss of YAP/TAZ in
adipocytes suggests that YAP/TAZ activation during obesity
promotes anti-apoptotic, pro-survival pathways, or inhibits pro-
apoptotic pathways. To determine whether YAP/TAZ are
involved in regulation of the pro-survival nuclear factor-κB (NF-
κB) signaling pathway, we analyzed the phosphorylation of NF-
κB in adipose tissue lysates from Ad-Yap/Taz-KO mice fed HFD
for 4 weeks but found no obvious difference in phosphorylation
of P65 compared to controls (Supplementary Fig. 4a). Deficiency
of YAP/TAZ also did not alter tumor necrosis factor-α (TNFα)-
induced P65 phosphorylation in primary adipocytes from wild-
type and Ad-Yap/Taz-KO mice fed HFD for 4 weeks (Supple-
mentary Fig. 4b). This indicates that YAP/TAZ are not critically
involved in NF-κB activation during obesity.
To understand the underlying mechanism by which YAP/TAZ
modulate adipocyte survival during obesity, we performed
expression profiling by RNA sequencing (RNA-seq) and
quantitative RT-PCR using total RNA isolated from white
adipocytes of Ad-Yap/Taz-KO mice and of wild-type littermates,
which had been fed HFD for 4 weeks. As expected, YAP/TAZ
target genes, such as Ctgf, Cyr61, AmotL2, and Lats2, showed
reduced expression in Ad-Yap/Taz-KO adipocytes (Fig. 4a and
Supplementary Fig. 4c). In addition, we found that the anti-
apoptotic genes Bcl2 and Bcl2l2 were downregulated, whereas the
pro-apoptotic gene Bim was upregulated in the absence of Yap/
Taz (Fig. 4a and Supplementary Fig. 4c). Interestingly, in
adipocytes from HFD-fed wild-type animals as well as from the
vWAT of obese humans, the pro-apoptotic factor BIM
(BCL2L11) was downregulated compared to lean controls (Fig. 4b,
c), and in chromatin immunoprecipitation (ChIP) assays we
found that YAP showed increased binding to a TEAD-binding
motif in the promoter region of Bim in adipocytes from HFD-fed
mice compared to animals fed an SD (Fig. 4d). The strong
upregulation of Bim expression in the absence of YAP/TAZ was
confirmed on the protein level in primary adipocytes isolated
from HFD-fed Ad-Yap/Taz-KO mice, as well as in adipocytes
differentiated from the SVF (stromal vascular fraction) of Ad-
Yap/Taz-KO mice in vitro (Fig. 4b, e, f), which also showed
increased apoptosis (Fig. 4g). Suppression of Yap and Taz
expression in differentiated 3T3-L1 adipocytes also resulted in
increased Bim expression and apoptosis (Fig. 4h–j), and small
interfering RNA (siRNA)-mediated suppression of Bim expres-
sion blocked the increase in apoptosis (Fig. 4i, j). Consistent with
this, suppression of Bim expression in epididymal adipocytes of
HFD-fed Ad-Yap/Taz-KO mice in vivo by viral transduction of a
corresponding short hairpin RNA (shRNA) resulted in a
significantly reduced number of crown-like structures and of
TUNEL-positive cells (Fig. 4k–m), and was accompanied by a
significant decrease in fat loss (Supplementary Fig. 4d). These
data indicate that YAP/TAZ suppress expression of the pro-
apoptotic gene Bim to promote adipocyte survival.
TNFα and IL-1β induce YAP/TAZ nuclear translocation and
YAP/TAZ transcriptional activity. To identify signals in fat
tissue that might induce YAP/TAZ activation during obesity, we
analyzed whether palmitic acid or several cytokines, including
TNFα, interleukin (IL)-1β, CCL2, and IL-6 are able to induce
YAP/TAZ target gene expression in 3T3-L1 adipocytes. Quanti-
tative RT-PCR analysis showed that expression of the YAP/TAZ
target genes Ctgf, Cyr61, and Ankrd1 was induced by TNFα or IL-
1β (Fig. 5a). Consistent with this, we detected increased YAP/
TAZ nuclear translocation in response to TNFα and IL-1β
(Fig. 5b and Supplementary Fig. 5a), and suppression of Yap/Taz
expression strongly inhibited TNFα- and IL-1β-induced YAP/
TAZ target gene expression (Fig. 5c and Supplementary Fig. 5b).
An involvement of TNFα and IL-1β in the activation of YAP and
TAZ in mouse adipocytes during obesity could be demonstrated
by treating animals with the TNFα inhibitor etanercept and the
IL-1β inhibitor anakinra. In HFD-fed mice, etanercept and ana-
kinra significantly reduced HFD-induced nuclear translocation of
YAP/TAZ, as well as upregulation of YAP/TAZ target gene
expression (Fig. 5d, e). In differentiated adipocytes, TNFα or IL-
1β did not change protein or phosphorylation levels of YAP/TAZ
(Supplementary Fig. 5c) and knockdown of the Hippo pathway
kinase LATS1/2 did not affect induction of YAP/TAZ target gene
expression by TNFα or IL-1β (Supplementary Fig. 5d). This
indicates that regulation of YAP/TAZ activity by TNFα or IL-1β
is independent of the Hippo pathway. Inhibition of RhoA, which
was activated by TNFα in 3T3-L1 adipocytes (Supplementary Fig.
5e) by C3-exoenzyme, depolymerization of actin by latrunculin B,
and inhibition of myosin II ATPase by blebbistatin attenuated
TNFα- and IL-1β-induced nuclear translocation of YAP/TAZ
(Fig. 5f and Supplementary Fig. 5f–h), as well as TNFα- and IL-
1β-induced YAP/TAZ target gene expression (Fig. 5g, f and
Supplementary Fig. 5i, j). To examine which RhoGEF protein is
involved in TNFα-induced RhoA activation in adipocytes, we
focused on ArhGEF2 (GEF-H1), which has been described to be
activated through the TNFα receptor45, on ArhGEF11
(PDZRhoGEF), which has been involved in adipocyte metabo-
lism46, as well as on the related RhoGEF proteins ArhGEF1 and
Fig. 2 Induction of Yap/Taz loss in mature white adipocyte leads to adipose death and increased adipogenesis during HFD feeding. a–c Wild-type
(WT, n= 8–9), iAd-Yap/Taz-KO (n= 9–11), iAd-Yap-KO (n= 6–7), and iAd-Taz-KO (n= 6) mice were fed HFD for 16 weeks. Shown are the body weight
development (a), glucose tolerance (b), and weight of vWAT and sWAT (c) after 16 weeks of HFD. d H&E-stained epididymal vWAT sections from WT
and iAd-Yap/Taz-KO mice after 16 weeks of HFD. Arrowheads point to crown-like structures. Scale bar: 50 µm. e Total adipocyte number in vWAT and
sWAT from WT and iAd-Yap/Taz-KO mice fed HFD for 16 weeks (n= 3 mice in both groups; at least 10 sections were analyzed per animal). f Number of
crown-like structures (CLS) in vWAT and sWAT from WT and iAd-Yap/Taz-KO mice fed HFD for 16 weeks (n= 4 mice per group; at least 10 view fields
were analyzed per animal). g Sections of vWAT from WT and iAd-Yap/Taz-KO mice stained with anti-CD68 antibody (green), CellMask (red), and DAPI.
Scale bar: 50 µm. The bar diagram shows the statistical evaluation of CD68-positive cells per view field (n= 4 mice per group; at least 10 sections per
animal were analyzed). h TUNEL-positive cells in sections of vWAT from WT and iAd-Yap/Taz-KO mice (n= 3 mice per group; at least 10 sections per
animal were analyzed). i Experimental design of analysis of adipogenesis in vivo using Adipoq-CreERT2;mT/mG mice. j, k Representative images (j) and
statistical analysis (k) of adipocyte tracing in Adipoq-CreERT2;mT/mG; Yapflox/flox;Tazflox/flox mice (KO), and Adipoq-CreERT2;mT/mG mice (WT) after
tamoxifen treatment and 8 and 16 weeks of HFD (n= 3 mice; at least 10 sections per animal were analyzed). Scale bars: 50 µm. Shown are mean values ±
SEM; *p≤ 0.05 and **p≤ 0.01 (two-way ANOVA in a, b and one-way ANOVA in c, and unpaired Student’s t-test in e–h, k). Source data are provided as a
Source Data file.
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ArhGEF12 (LARG). Whereas knockdown of ArhGEF1, Arh-
GEF11, and ArhGEF12 had no effect on TNFα-induced upre-
gulation of YAP/TAZ target genes (Supplementary Fig. 5k),
knockdown of ArhGEF2 blocked the TNFα effect (Fig. 5i). This
suggests that ArhGEF2- and RhoA-mediated actomyosin con-
tractility is required for TNFα- and IL-1β-induced YAP/TAZ
nuclear translocation and subsequent transcriptional activity.
To identify additional intracellular signaling pathways acti-
vated by TNFα and IL-1β, which are involved in YAP/TAZ
activation by both cytokines in adipocytes, we tested the effect of
various protein kinase inhibitors on TNFα- and IL-1β-induced
YAP/TAZ target gene expression. Whereas inhibition of mitogen-
activated protein-kinase kinase, inhibitor of NF-κB-kinase,
phosphoinositide-3-kinase, and p38 kinase had no effect
(Supplementary Fig. 6a), inhibition of c-Jun N-terminal kinase
(JNK) strongly attenuated TNFα- and IL-1β-induced YAP/TAZ
target gene expression (Fig. 6a and Supplementary Fig. 6b). A
requirement of JNK for TNFα- and IL-1β-induced YAP/TAZ
transcriptional activity was validated by knockdown of Jnk, which
also blocked TNFα- and IL-1β-induced activation of YAP/TAZ
target genes (Fig. 6b and Supplementary Fig. 6c). C3-exoenzyme
and latrunculin B did not affect TNFα-induced JNK phosphor-
ylation (Supplementary Fig. 6d), indicating that Rho-mediated
signaling is not required for TNFα- and IL-1β-induced JNK
activation. Although disruption of the actin cytoskeleton by
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Fig. 3 Ad-Yap/Taz-KO mice exhibit increased adipocyte cell death and lipodystrophy. a–c Wild-type (WT, n= 6) and Ad-Yap/Taz-KO mice (n= 5–8)
were fed HFD for 14 weeks starting at 6 weeks of age. Shown are the development of body weight (a), glucose tolerance after 12 weeks of HFD (b), as well
as weight of vWAT and sWAT (c). d, e Wild-type (WT, n= 3–4) and Ad-Yap/Taz-KO mice (n= 4) were fed HFD for 4 or 14 weeks (w). Shown are the
quantification of TUNEL-positive cells in sections of vWAT from WT and Ad-Yap/Taz-KO mice (d), and H&E-stained epididymal vWAT sections
(14 weeks) (e). Arrowheads in e indicate crown-like structures (CLS). Scale bar: 50 µm. The bar diagram (e) shows the number of CLS in vWAT from WT
and Ad-Yap/Taz-KO mice (n= 4 mice in both groups; at least 10 sections were analyzed per animal). f, g Paraffin sections of vWAT from WT and Ad-
Yap/Taz-KO mice stained with anti-Perilipin-1 (red) and DAPI (f) or with anti-CD68 antibody (green), CellMask (red), and DAPI (g). Scale bars: 50 µm.
The bar diagram shows the statistical evaluation of CD68+ cells per view field (n= 5 mice per group; at least 10 sections were analyzed per animal).
h, i Quantitative RT-PCR showing mRNA expression of M1 and M2 macrophage marker genes (h) and of adipocyte-specific marker genes (i) in vWAT
from WT and Ad-Yap/Taz-KO mice fed HFD for 14 weeks (n= 4 mice per group). Data are presented as the mean ± SEM; *p≤ 0.05 and **p≤ 0.01 (two-
way ANOVA in a, b and unpaired Student’s t-test in c–e, g–i). Source data are provided as a Source Data file.
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Fig. 4 YAP/TAZ promote adipocyte survival by suppression of Bim expression. a Quantitative RT-PCR showing mRNA expression of Yap, Taz, and their
target genes including pro- and anti-apoptotic factors in white adipocytes isolated from WT and Ad-Yap/Taz-KO mice fed HFD for 4 weeks (n= 3 mice
per group). b RNA-seq data showing expression of Bim (Bcl2l11) in white adipocytes isolated fromWT and Ad-Yap/Taz-KO mice fed HFD or standard diet
for 4 weeks (n= 2 mice per group). c Expression of Bim in isolated adipocytes from the vWAT of lean (BMI < 25) and obese humans (BMI > 30) (n= 9 in
both groups). d Chromatin immunoprecipitation (ChIP) PCR of the TEAD-binding site in the Bim promoter region in lysates of vWAT prepared from WT
mice fed standard diet (SD) or HFD for 4 weeks using an anti-YAP antibody (#4912, Cell Signaling Technology) (n= 4 mice per group). e, f Western blot
analysis showing BIM protein level in white adipocyte isolated from WT and Ad-Yap/Taz-KO mice (KO) fed HFD for 4 weeks (e) and in adipocytes
differentiated from the SVF of WT and Ad-Yap/Taz-KO mice (KO) (f). g Apoptotic cell death detected by TUNEL staining of adipocytes differentiated from
SVF of WT and Ad-Yap/Taz-KO mice (n= 5 mice per group). h Quantitative RT-PCR showing mRNA expression of YAP/TAZ target genes in
differentiated 3T3-L1 adipocytes treated with control siRNA or siRNA directed against Yap and Taz (n= 3). i, j Differentiated 3T3-L1 adipocytes were
treated with control siRNA or siRNA directed against Yap, Taz, and Bim, and western blot analysis was performed to analyze protein levels of BIM, YAP,
TAZ, and GAPDH (i). In parallel, cells were analyzed by TUNEL staining to determine cell apoptosis (j) (n= 4). k Bim expression in adipocytes isolated
from vWAT 4 weeks after injection of adeno-associated virus transducing control shRNA (AAV-Con) or shRNA directed against Bim (AAV-shBim) fed
HFD (n= 3 mice per group). l, m Quantification of crown-like structures (CLS) (l) and of TUNEL-positive cells (m) in sections of vWAT from WT and Ad-
Yap/Taz-KO mice 4 weeks after injection of adeno-associated virus transducing control shRNA (AAV-Con) or shRNA directed against Bim (AAV-shBim)
and fed HFD (n= 3 mice per group, at least 10 sections were analyzed per animal). Data are presented as the mean ± SEM; *p≤ 0.05 and **p≤ 0.01
(unpaired Student’s t-test in a, c, g, h and one-way ANOVA in b, d, j–m). Source data are provided as a Source Data file.
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nuclear localization, inhibition of JNK activation had no effect
(Figs. 5f and 6c, and Supplementary Fig. 5g), indicating that JNK
does not regulate YAP/TAZ function on the level of nuclear
translocation. As the YAP/TAZ/TEAD complex has been shown
to functionally interact with AP-1 that synergistically regulates
YAP/TAZ target gene expression47, and as JNK phosphorylates
and regulates c-Jun, a component of AP-148, we tested whether
siRNA-mediated suppression of c-Jun affects TNFα- and IL-1β-
induced YAP/TAZ target gene expression. We found that
suppression of c-Jun expression attenuated TNFα- and IL-1β-
induced YAP/TAZ target gene expression (Fig. 6d and Supple-
mentary Fig. 6e), which indicates that JNK and c-JUN mediate
TNFα-induced YAP/TAZ transcriptional activity. Taken together,
these data suggest that RhoA-mediated actomyosin contractility
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is required for TNFα- and IL-1β-induced YAP/TAZ nuclear
localization, whereas JNK/c-JUN is essential for YAP/TAZ
transcriptional activity.
Discussion
YAP and TAZ are transcriptional regulators that integrate
metabolic pathways, mechanical cues, and various signaling
pathways to control different cellular functions including pro-
liferation, differentiation, and cell survival27–29. Based on our
initial observation that YAP and TAZ, as well as a characteristic
YAP/TAZ transcriptional program were activated in mouse and
human white adipocytes during the development of obesity, we
found that loss of YAP and TAZ expression did not affect adi-
pocyte function in normal healthy mice. However, in animals fed
a HFD, loss of YAP and TAZ resulted in lipodystrophy including
massive adipocyte death, a compensatory increase in adipogenesis
and infiltration by immune cells. This indicates that YAP/TAZ
signaling protects mature adipocytes from cell death during
obesity.
Given the YAP/TAZ activation in adipocytes during obesity,
the question arises how YAP/TAZ are activated during expansion
of the adipose tissue. As adipocytes increase in size during obe-
sity, they experience increased mechanical stress due to com-
pressive forces or strain exerted by the extracellular matrix on
expanding adipocytes49,50. There is also an increase in connective
fiber content in obese adipose tissue, which results in an increase
in overall rigidity of the adipose tissue and which has been shown
to contribute to increased cell death in the obese adipose tissue51.
In fact, YAP and TAZ activity is controlled by mechanical signals,
such as extracellular matrix rigidity, shear stress, and
stretching35,52,53, and cytoskeletal tension has been linked to
YAP/TAZ activity28,35–37. A stiff environment favors YAP
nuclear localization and activation, whereas attachment to soft
substrates increases cytoplasmic retention of YAP35. Recent work
has shown that integrin adhesion to the extracellular matrix and
Fig. 5 TNFα regulates YAP/TAZ transcriptional activity in adipocytes. a Quantitative RT-PCR showing mRNA expression of YAP/TAZ target genes in
response to TNFα (1.1 nM), IL-1β (5.9 nM), IL-6 (0.8 nM), CCL2 (1.2 nM), and palmitic acid (p.a., 500 nM) in differentiated 3T3-L1 adipocyte (n= 3 per
group). b Differentiated 3T3-L1 adipocytes were incubated without or with 1.1 nM TNFα for 6 h, then cytosolic and nuclear fractions were analyzed by
immunoblotting using antibodies against YAP/TAZ, α-Tubulin (cytoplasmic marker), and Lamin A/C (nuclear marker). The dashed line indicates the
margins of a region, which was cut out. c, g, h Differentiated 3T3-L1 adipocytes were treated with control siRNA or siRNA directed against Yap/Taz (c) or
were pretreated with 2.5 µM latrunculin B (latr B), 20 µM blebbistatin (blebb) for 30min (g), or with 1 µg/ml of C3-exoenzyme (h) for 6 h. Thereafter, cells
were incubated without or with 1.1 nM TNFα for 8 h and expression of YAP/TAZ target genes was analyzed (n= 3). d Quantification of YAP/TAZ
localization to the nucleus (N) or cytosol (C) in the visceral (vWAT) from standard diet (SD)-fed (n= 3) and HFD-fed mice (n= 3) treated without or with
etanercept and anakinra by intraperitoneal injection. e Expression of YAP/TAZ target genes in white adipocyte isolated from the vWAT of mice fed HFD
(n= 3) or standard diet (SD) and treated without or with etanercept and anakinra (n= 3). f Differentiated 3T3-L1 adipocytes were preincubated with C3-
exoenzyme (C3) or latrunculin B (latr B). Thereafter, cells were incubated without or with 1.1 nM TNFα for 6 h, and cytosolic and nuclear fractions were
analyzed by immunoblotting using antibodies against YAP, TAZ, Lamin A/C, and α-Tubulin. i Differentiated 3T3-L1 adipocytes were treated with control
siRNA or siRNA directed against Arhgef2. Thereafter, cells were incubated in the absence or presence of TNFα (1.1 nM) and expression of YAP/TAZ target
genes was determined (n= 4). Data are presented as the mean ± SEM; *p≤ 0.05, **p≤ 0.01, and ***p≤ 0.001 (one-way ANOVA). Source data are
provided as a Source Data file.
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Fig. 6 JNK and c-JUN mediate TNFα-induced YAP/TAZ transcriptional activity. a–d Differentiated 3T3-L1 adipocytes were incubated in the absence or
presence of the JNK inhibitor SP600125 (JNKi, 5 µM) (a, c), latrunculin B) (latr B, 2.5 µM) (c), or were treated with control siRNA or siRNA directed against
Jnk1 and 2 (b) or c-Jun (d). Thereafter, cells were incubated in the absence or presence of TNFα (1.1 nM), and expression of YAP/TAZ target genes was
determined (n= 3) (a, b, d) or cytosolic and nuclear fractions were analyzed by immunoblotting using antibodies against YAP and TAZ, Lamin A/C or α-
Tubulin (c). Shown are mean values mean ± SEM; *p≤ 0.05, **p≤ 0.01, and ***p≤ 0.001 (one-way ANOVA). Source data are provided as a Source
Data file.
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integrin signaling, as well as RhoA-mediated signaling and
actomyosin-driven contractility play important roles in
mechanical regulation of YAP/TAZ activity28,54–58, which
appears to be largely independent of the Hippo pathway35,59. In
addition, actomyosin-mediated tension has been shown to reg-
ulate the thermogenic capacity of brown adipocytes through YAP
and TAZ60. However, it is not known whether a similar
mechanism exists in white adipocytes. Our data show that inhi-
bition of RhoA-mediated signaling, latrunculin B-induced depo-
lymerization of actin, and myosin II ATPase inhibition by
blebbistatin reduced cytokine-induced YAP/TAZ activation in
differentiated adipocytes, suggesting that increased cytoskeletal
tension in obese adipocytes contributes to YAP/TAZ activation
during obesity.
The enlargement of the adipose tissue during obesity is
accompanied by the development of a chronic low-grade
inflammation of the adipose tissue, which includes infiltration
of the adipose tissue by macrophages and increased levels of
cytokines13–19. By testing several mediators that are increased in
the obese adipose tissue, we identified TNF-α and IL-1β, which
have been shown to be produced by adipocytes and cells of the
SVF including infiltrating macrophages in obese mice and
humans61–65, as potent activators of adipocyte YAP/TAZ. This
suggests that inflammatory mediators produced in the obese
adipose tissue contribute to adipocyte YAP/TAZ activation dur-
ing obesity. TNF-α and IL-1β can activate several intracellular
signaling pathways including extracellular signal-regulated kinase,
IKK/NF-κB-signaling, p38, and JNK66. By pharmacological
inhibition and siRNA-mediated knockdown, we identified JNK as
a critical signaling component in cytokine-induced YAP/TAZ
activation in adipocytes. Although inhibition of JNK had no effect
on cytokine-induced nuclear translocation of YAP/TAZ, it
strongly inhibited cytokine-induced activation of the YAP/TAZ
transcriptional program, which we found to also require c-JUN, a
component of AP-148. As the YAP/TAZ/TEAD complex has been
shown to functionally interact with AP-1 to synergistically reg-
ulate target gene expression47, we conclude that a similar
mechanism is also operating in adipocytes. As a major mechan-
ism mediating cytokine-induced YAP/TAZ nuclear translocation,
we identified RhoA-mediated actomyosin contractility, whereas
blockade of the Hippo pathway component LATS1/2 had no
effect on cytokine-induced YAP/TAZ nuclear translocation. This
is consistent with several reports indicating that Rho/actomyosin-
mediated nuclear translocation of YAP/TAZ occurs indepen-
dently of the Hippo pathway34,35,67.
Expansion of the adipose tissue during obesity is accompanied
by increased mechanical, metabolic, and inflammatory stress, as
well as increased adipocyte cell death68. As we observed massive
apoptotic adipocyte cell death in the absence of YAP/TAZ in
mature adipocytes during obesity, activation of YAP/TAZ during
obesity may either promote anti-apoptotic, pro-survival pathways
or inhibit pro-apoptotic pathways. The inflammatory NF-κB
pathway is also important for adipocyte survival during obesity,
as loss of signaling components of this pathway results in
increased apoptotic death of adipocytes during obesity24,26. We
could largely exclude that YAP/TAZ have an effect on IKK/NF-
κB pro-survival signaling, as loss of YAP/TAZ did not affect
TNF-α-induced activation of NF-κB in vitro and as NF-κB
activity was not altered in adipocytes from obese Ad-Yap/Taz-KO
mice compared to controls.
When analyzing transcriptomic changes in white adipocytes of
Ad-Yap/Taz-KO mice fed HFD for 4 weeks compared to wild-
type littermates, we observed that the anti-apoptotic genes Bcl2
and Bcl2l2 were downregulated, and that the pro-apoptotic gene
Bim was strongly upregulated in the absence of YAP/TAZ. This is
consistent with previous data, which showed that, during
embryonic stem cell (ESC) differentiation, YAP attenuates
apoptosis primarily through transcriptional upregulation of anti-
apoptotic factors, including BCL2, BCL2L1, and MCL-169, as well
as with observations, which showed that YAP/TAZ promote cell
survival through suppression of the pro-apoptotic protein BIM,
whereas YAP/TAZ knockdown increased BIM expression70.
Similarly, it has been shown that overexpression of YAP or TAZ
suppresses BIM expression71,72. In differentiated adipocytes
in vitro, we could show that increased apoptotic cell death
induced by knockdown of YAP/TAZ, which was accompanied by
increased BIM expression, could be rescued by knockdown of
Bim. Thus, we conclude that increased activation of YAP/TAZ in
obese adipocytes suppresses expression of pro-apoptotic BIM and
promotes expression of anti-apoptotic factors such as Bcl2 and
Bcl2l2, and that these transcriptional regulatory effects contribute
to the protective effect of YAP/TAZ against increased adipocyte
cell death during obesity. Targeting YAP/TAZ signaling may
provide a novel therapeutic strategy to treat obesity by slowing
the expansion of the white adipose mass during hypercaloric diet.
Methods
Reagents. Tamoxifen (catalog number T5648), collagenase II (catalog number
C6885), wortmannin (catalog number W3144), latrunculin B (catalog number
428020), and IL-6 (catalog number I1395) were from Sigma-Aldrich. SC514 was
from Santa Cruz Biotechnology (catalog number 354812-17-2). SP600125 (catalog
number S5567) and p38 MAPK inhibitor III (catalog number 506148) were
obtained from Merck Chemicals GmbH. Exoenzyme C3 transferase was obtained
from Cytoskeleton (catalog number CT03-A). Mouse TNFα was purchased from
PeproTech (catalog number 315-01 A). IL-1β was from Life Technologies GmbH
(catalog number 10139-HNAE). CCL2 (catalog number 479-JE-10) was from Bio-
Techne GmbH. The following antibodies were obtained from Cell Signaling
Technology: anti-YAP/TAZ (#8418, 1:1000), anti-YAP (#4912, 1:1000), anti-
phospho-YAP (Ser127) (#4911, 1:1000), anti-phospho-TAZ (Ser89) (#59971,
1:1000), anti-Lamin A/C (#2032, 1:1000), anti-GAPDH (#2118, 1:3000), anti-
phospho-JNK (Thr183/Tyr185) (#9251, 1:1000), anti-IκBα (#4812, 1:1000), anti-
P65 (#4764, 1:1000), anti-phospho-P65 (Ser536) (#3033, 1:1000), and anti-BIM
(#2933, 1:1000). Anti-TAZ (#HPA007415, 1:1000) and anti-α-Tubulin (#T9026,
1:3000) were from Sigma-Aldrich. Anti-mouse and rabbit horseradish peroxidase
(HRP)-conjugated secondary antibodies were from Cell Signaling Technology.
Animals. Mice carrying floxed alleles of Yap1 (Yap1tm1a(KOMP)Mbp) were obtained
from the Knockout Mouse Project (KOMP) Repository (KOMP, Davis, California,
USA). ESCs carrying a targeted allele of Taz (Wwtr1tm1a), which after removal of a
cassette flanked by FRT (flippase recognition target) sites allows for Cre-mediated
recombination, were purchased from EUCOMM (Helmholtz Zentrum München).
ESC clones were injected into C57BL/6 blastocysts and were transferred to pseu-
dopregnant females. Chimeric offspring were bred with C57BL/6 mice to produce
heterozygous animals. Germline transmission was confirmed in the F1 generation
using a PCR genotyping strategy. To delete the selection cassette, mice were crossed
to Flp-deleter mice73. Adipocyte-specific Yap/Taz-deficient mice (iAd-Yap/Taz-
KO) were generated by crossing Yapflox/flox;Tazflox/flox mice with Adipoq-CreERT2
transgenic mice41. For adipocyte pulse-chase experiments, iAd-Yap/Taz-KO
and control animals were crossed with the Cre reporter line Gt(ROSA)
26Sortm4(ACTB-tdTomato,-EGFP)Luo/J (mT/mG)43 obtained from The Jackson
Laboratory (JAX stock number 007676). Yapflox/flox;Tazflox/flox mice were also
mated with Adipoq-Cre mice44 to generate Ad-Yap/Taz-KO mice. For induction of
Cre-mediated recombination in iAd-Yap/Taz-KO mice, 1 mg of tamoxifen was
injected intraperitoneally for 5 consecutive days at the age of 5 weeks. Animals
were fed SD (SC, Altromin) or a Western-type HFD containing 30% fat (ssniff)
starting from the age of 6 weeks with water ad libitum. Tamoxifen-treated Yapflox/
flox;Tazflox/flox littermates served as controls. For in vivo experiments, male animals
were used at the age of 8–12 weeks if not stated otherwise, whereas adipose tissue
from male mice were tested in several in vitro experiments as indicated. Animal
care and experimental procedures followed were compliant with ethical regulations
and were approved by the local animal welfare authorities and committees
(Regierungspräsidia Karlsruhe and Darmstadt).
Cell culture. Primary white adipocytes and stromal vascular cell fraction from
mouse epididymal fat pads and human primary white adipocytes were isolated as
described previously24. All human samples were collected with the informed
consents from the donors following the bioethics and safety regulations. Isolated
primary white adipocytes were cultured at 37 °C and 5% CO2 in Dulbecco’s
modified Eagle’s medium with 10% fetal bovine serum and antibiotic solution.
3T3-L1 preadipocytes (obtained from American Type Culture Collection) were
differentiated into mature adipocytes as previously described74.
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siRNA-mediated knockdown. A suspension of differentiated 3T3-L1 adipocytes
was transfected with siRNA using Lipofectamine RNAiMax transfection reagent
(Invitrogen) according to the manufacturer’s instruction and seeded on collagen-
coated plates. The targeted sequences of mouse siRNAs directed against RNAs
encoding Yap, Taz, Lats1, Lats2, Jnk1, Jnk2, c-Jun, Bim, Rhogef1, Rhogef2, Rho-
gef11, and Rhogef12 were as follows: Yap, 5′-GCTAGATAAAGAAAGCTTT-3′
and 5′-CCAATAGTTCCGATCCCTT-3′; Taz, 5′-GAATCAGCCTCTGAATCAT-
3′ and 5′-GTCTGAAGATCTGATCCCT-3′; Lats1, 5′-GCAACATTCAATT
AACCGA-3′; Lats2, 5′-CCATGAAGACTCTCAGGAA-3′; Jnk1, 5′-CAAGA
GATTTGTTATCCAA-3′, 5′-GAAGCAAACGTGACAACAA-3′, 5′-GTTCTTAT
GAAGTGTGTTA-3′, and 5′-TAAATACGCTGGATATAGC-3′; Jnk2, 5′-CC
GCAGAGTTCATGAAGAA-3′, 5′-GCGGATCTCTGTGGACGAA-3′, 5′-AAA-
GAGAGCATGCGATTGA-3′, and 5′-GCATTCAGCTGGTATCATT-3′; c-Jun,
5′-AGCGTTCGTTATCACAATAAA-3′, 5′-GTGCCTACGGCTACAGTAA-3′,
and 5′-GTAACCCTAAGATCCTAAA-3′; Bim, 5′-GTGTTTACATGTGG
CGTGT-3′ and 5′-GCCAATTTATGGATGATTT-3′; Arhgef1, 5′-TTGGCT
GAACTTGATAGCAGA-3′ and 5′-CTCCAGATTGTCGACATCTAA-3′; Arhgef2,
5′-CACCAAGGCCTTAAAGCTCTA-3′ and 5′-ATCAATCTTTATGGACT
TCTA-3′; Arhgef11, 5′-CAGAAGTTTATCAGCAGACAA-3′ and 5′-CTGGGA
GATTCTACACCTGAA-3′; Arhgef12, 5′-CAGCAGCTTGTTAGCAGAGAA-3′
and 5′-AAGAATTCAAATATTAAATAA-3′.
Glucose tolerance test. Intraperitoneal glucose tolerance test and insulin toler-
ance test were performed as described previously24. Briefly, after overnight fasting,
glucose was administered intraperitoneally at a dose of 1.5 mg glucose per g body
weight for HFD-fed mice and 2 mg glucose per g body weight for mice fed SD.
Blood glucose levels were measured in blood taken from the tail vein prior to or at
the indicated times after glucose administration using a glucometer (Accu-Chek
Aviva, Roche). Insulin sensitivity was determined by intraperitoneal injection of
0.75-1 units of insulin per kg body weight and measuring of glucose levels in blood
taken from the tail vein before and at the indicated times after insulin injection in
mice fasted for 6 h.
Adipocyte pulse-chase experiments. Adipocyte pulse-chase experiments were
performed as described42. Mice were treated with 1 mg/d tamoxifen at the age of
5 weeks by intraperitoneal injection for five consecutive days. Mice were then
placed on HFD or remained on SD for an 8-week or a 16-week chase period.
Inguinal and epididymal WAT were taken from several regions throughout the
depot and were analyzed by whole mount confocal microscopy for tdTomato and
eGFP expression. Per mouse, at least 300 (sWAT) or 2000 (vWAT) adipocytes were
counted from multiple images.
Administration of adeno-associated virus. Adeno-associated viral (AAV) vectors
of serotype 8, carrying a scrambled sequence (AAV-Ctrl) or an shRNA directed
against the mouse Bim RNA (AAV-Bim-shRNA) were obtained from Vigen
Bioscience. For delivery of virus to the epididymal WAT, mice were anesthetized
with 2% isoflurane and a laparotomy was performed to expose the epididymal fat
pad under a sterile hood. Virus were diluted to 2.5 × 1010 viral genomes/ml in
sterile phosphate-buffered saline (PBS) and a total amount of 50 μl Bim shRNA
virus or control virus was injected at five different sites of each fat pad using a
0.3 cm3 31 G insulin syringe.
Etanercept and anakira treatment in vivo. Mice fed HFD for 4 weeks were
injected during the fourth week with 10 mg/kg etanercept and 25 mg/kg anakira
intraperitoneally for 7 consecutive days. Afterwards, animals were killed for fat
tissue collection and adipocyte isolation, or whole mount tissue staining.
Histology and immunohistochemistry. Tissues were fixed by paraformaldehyde
(4%), dehydrated in an ethanol gradient, and then transferred to xylene solution for
embedding in paraffin. Five-micrometer sections were stained with hematoxylin-
eosin and images were analyzed with light microscopy. Adipocyte area in sections
was determined in more than 100 cells per condition using ImageJ (NIH). Adi-
pocyte number was calculated as described previously75. TUNEL assay was per-
formed on paraffin sections (5 µm) of WAT following the instructions of the In
Situ Cell Death Detection Kit (Roche Applied Sciences). For immunohistochemical
staining, paraffin sections (5 µm) were placed in a microwave oven for heat-
induced epitope retrieval. The following antibodies were used: anti-CD68 (Bio-rad,
MCA1957, 1:100) and anti-Perilipin-1 (Cell Signaling Technology, 3470, 1:100).
CellMask™ Orange plasma membrane stain (Life Technologies, Thermo Fisher
Scientific, C10045) was used to visualize the plasma membrane. Whole fat tissue
mount for YAP/TAZ localization (using anti-YAP/TAZ antibody #8418, 1:100, Cell
Signaling Technology) and adipocyte pulse-chase experiments was performed as
described76. Immunofluorescence imaging was performed using a Leica TCS SP5
confocal microscope.
Quantitative RT-PCR and RNA-seq. Total RNA was isolated from adipocytes or
fat tissue using the RNeasy lipid tissue Mini Kit (Qiagen, Valencia, CA, USA) and
DNA was removed using the QIAGEN RNase-Free DNase Set following the
manufacturer’s instructions. cDNA was synthesized using ProtoScript® II reverse
transcriptase (New England Biolabs). Quantitative RT-PCR was performed using
LightCycler 480 Real-Time PCR detection System (Roche Molecular Biochemicals,
Mannheim, Germany) according to the manufacturer’s instructions. Relative
mRNA expression was normalized to GAPDH. PCR primers are listed under
Supplementary Table 1. For RNA-seq, RNA and library preparation integrity were
verified with a BioAnalyzer 2100 (Agilent) or LabChip Gx Touch 24 (Perkin
Elmer). Twenty nanograms of total RNA was used as starting material for ribo-
somal depletion with RiboGone-Mammalian (Clontech) followed by library pre-
paration using SMARTer Stranded Total RNA Sample Prep Kit (Clontech).
Sequencing was performed on the NextSeq500 instrument (Illumina) using v2
chemistry, resulting in an average of 35M reads per library with 1 × 75 bp single
end setup. The resulting raw reads were assessed for quality, adapter content, and
duplication rates with FastQC (Andrews S. 2010, FastQC: a quality control tool for
high-throughput sequence data. Available online at: http://www.bioinformatics.
babraham.ac.uk/projects/fastqc). Reaper version 15-065 was employed to trim
reads after a quality drop below a mean of Q20 in a window of 20 nucleotides77.
Only reads between 15 and 75 nucleotides were cleared for further analyses.
Trimmed and filtered reads were aligned vs. the Ensembl mouse genome version
mm10 (GRCm38) using STAR 2.5.2b with the parameter
“–outFilterMismatchNoverLmax 0.1” to increase the maximum ratio of mis-
matches to mapped length to 10%78. The number of reads aligning to genes was
counted with featureCounts 1.5.1 tool from the Subread package79. Only reads
mapping at least partially inside exons were admitted and aggregated per gene.
Reads overlapping multiple genes or aligning to multiple regions were excluded.
Differentially expressed genes were identified using DESeq2 version 1.14.180. Only
genes with a minimum fold change of ±1.5 (log2 ± 0.59), a maximum
Benjamini–Hochberg corrected p-value of 0.05, and a minimum combined mean of
5 reads were deemed to be significantly differentially expressed. The Ensemble
annotation was enriched with UniProt data (release 24.03.2017) based on Ensembl
gene identifiers81.
Chromatin immunoprecipitation. ChIP analysis was performed as described
previously82. vWAT from mice fed with SD or HFD for 4 weeks was washed with
PBS and crosslinked with 1% formaldehyde for 10 min. Samples were lysated in
adipocyte lysis buffer (5 mM PIPES pH 8.0, 85 mM KCl, and 0.5% NP-40) and
homogenized using a Retsch MM 300 TissueLyser Mixer Mill. Then, samples were
centrifuged (5 min, 700 × g, 4 °C), pelleted nuclei were resuspended in SDS lysis
buffer (1% SDS, 10 mM EDTA pH 8.1, and 50 mM Tris·HCl pH 8.1) and sheared
with a Bandelin Sonopuls hd 2070 (18 pulses, each pulse 10 s at 100% of the
sonicator’s amplitude) to generate DNA fragments of 200–1000 bp length. The
chromatin was precleared and incubated with YAP antibody (#4912, Cell Signaling
Technology) or IgG overnight under rotation. Complexes were pulled down with
20 µl Magnet ChIP A beads (Millipore) and eluted in elution buffer containing 1%
SDS and 100 mM NaHCO3. Samples were digested with proteinase K, and DNA
was extracted using PCR Clean-up kit (Macherey-Nagel). Samples were analyzed
by qPCR using primers Bimfw 5′-TGGATAGACAGTTCCTGGCG-3′ and Bimrev
5′-CGGGCACGACAAGCATATAA-3′.
Western blottings. The nuclear and cytoplasmatic fraction of adipocytes were
separated using NE-PER™ Nuclear and Cytoplasmic Extraction Reagents (Thermo
Scientific). Mouse fat tissues or adipocytes were collected, snap-frozen in liquid
nitrogen and stored at −80 °C. For protein extraction, ~50 mg frozen tissue was
homogenized for 2 min at 30 Hz using a Retsch MM 300 TissueLyser Mixer Mill in
200 μl lysis buffer (50 mM Tris pH 7.5, 2 mM EDTA, 2 mM EGTA, 0.5 M man-
nitol, 1% Triton X-100, as well as phosphatase inhibitors (10 mg/ml leupeptin,
pepstatin A, 4-(2-aminoethyl) benzenesulfonyl-fluoride, and aprotinin) and pro-
tease inhibitors (PhosSTOP, Roche))83. Extracts were spun down, and fat layer and
cell debris were removed. Proteins were separated by SDS-polyacrylamide gel
electrophoresis and analyzed by immunoblotting using the indicated antibodies.
For detection, PierceTM ECL Western Blotting Substrate (Thermo Scientific) or
Immobilon Western Chemiluminescent HRP Substrate (Merck) were used.
Study approval. The work on human adipocyte samples was approved by the
ethical committee of Xi’an Jiaotong University (XJTU2018-249 and XJTU2019-12)
and conforms to the guidelines of the 2000 Helsinki declaration. Written informed
consent was obtained from all subjects before their participation. All procedures of
animal care and use in this study were approved by the local animal welfare
authorities and committees (Regierungspräsidia Karlsruhe and Darmstadt).
Statistics. Trial experiments or experiments done previously were used to deter-
mine sample size with adequate statistical power. Samples were excluded in cases
where RNA/cDNA quality or tissue quality after processing was poor (below
commonly accepted standards). Animals were excluded from experiments if they
showed any signs of sickness. The investigator was blinded to the group allocation
and during the experiment. Data represent biological replicates. In all studies,
comparison of mean values was conducted with unpaired, two-tailed Student’s t-
test or one-way or two-way analysis of variance with Bonferroni’s post hoc test. In
all analyses, statistical significance was determined at the 5% level (P < 0.05).
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Depicted are mean values ± SEM as indicated in the figure legends. Statistical
analysis was performed with Prism5 or Prism6 (GraphPad), or Excel (Microscoft)
software.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The RNA-seq data are available in GEO repository under the accession
GSE138911. Source data are provided with this paper.
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